中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (49): 9307-9310.doi: 10.3969/j.issn.1673-8225.2011.49.044

• 干细胞临床实践 clinical practice of stem cells • 上一篇    

非清髓性异基因造血干细胞移植治疗高龄白血病

陆婧媛，鹿全意   

  1. 福建医科大学协和临床医学院，厦门中山医院，福建省厦门市361004
  • 收稿日期:2011-05-20 修回日期:2011-07-14 出版日期:2011-12-03 发布日期:2011-12-03
  • 通讯作者: 鹿全意，博士，教授，主任医师，硕士生导师，福建医科大学协和临床医学院，厦门中山医院血液科，福建省厦门市 361004 luquanyi@xmu.edu.cn
  • 作者简介:陆婧媛，女，1988年生，福建省惠安县人，汉族，福建医科大学2005级临床医学七年制在读生，主要从事内科血液学研究。 jennylu087@yahoo.com.cn

Non-myeloablative allogeneic hematopoietic stem cells transplantation for the treatment of elderly patients with acute leukemia

Lu Jing-yuan, Lu Quan-yi   

  1. Xiamen Zhongshan Hospital, Union Clinical Medical College of Fujian Medical University, Xiamen  361004, Fujian Province, China
  • Received:2011-05-20 Revised:2011-07-14 Online:2011-12-03 Published:2011-12-03
  • Contact: Lu Quan-yi, Doctor, Professor, Chief physician, Master’s supervisor, Hematology Department, Xiamen Zhongshan Hospital, Union Clinical Medical College of Fujian Medical University, Xiamen 361004, Fujian Province, China luquanyi@xmu.edu.cn
  • About author:Lu Jing-yuan, Xiamen Zhongshan Hospital, Union Clinical Medical College of Fujian Medical University, Xiamen 361004, Fujian Province, China jennylu087@yahoo.com.cn

PDF

338

摘要：

背景：非清髓异基因造血干细胞移植减轻了预处理强度，减少了移植相关的死亡。
目的：分析非清髓性异基因造血干细胞移植治疗老年急性白血病的疗效及其安全性。
方法：71岁急性单核细胞白血病M5b 患者1例，行非清髓性异基因造血干细胞移植。供者为患者同胞弟弟，60岁，HLA 5个位点相合，ABO血型相同。预处理用药包括采用氟达拉滨、塞替派、环磷酰胺和马利兰针剂。移植物抗宿主病预防用抗胸腺球蛋白、巴利昔单抗、环孢素A、麦考酚酯肠溶片及丙种球蛋白,移植后并发症防治和支持治疗：更昔洛韦防治巨细胞病毒感染、前列腺素E1、丹参、肝素及熊去氧胆酸防治肝静脉闭塞症，预处理后外周血中性粒细胞低于0.5×109 L-1时开始予粒细胞集落刺激因子5 μg/(k g•d)促进造血重建。必要时输注辐照的浓缩红细胞和血小板，供者采用粒细胞集落刺激因子，连用 7 d，第6，7天采集外周血造血干细胞，当天输注给患者。
结果与结论：移植后28 d完成造血重建。移植后50 d，行STR检测结果显示供受者100%一致。移植后+20~30 d陆续出现“出血性膀胱炎”、“败血症(洋葱伯克霍尔德菌胞菌)”，移植后2个月出现黄疸、肝功能损害，诊断“急性移植物抗宿主病Ⅲ度(肝脏，3级) ”，经过抗感染、保肝、调整免疫抑制药物治疗后病情缓解。结果表明采用以氟达拉滨为基础的非清髓性外周血造血干细胞移植治疗有多种合并症老年急性白血病是一种有效安全的方法。

关键词: 白血病, 造血干细胞移植, 异基因, 非清髓性, 并发症

Abstract:

BACKGROUND: Non-myeloablative allogeneic hematopoietic stem cells transplantation can reduce the intensity of conditioning regimen, and decrease the transplantation related mortality rate.
OBJECTIVE: To analyze the efficacy and safety of non-myeloablative allogeneic hematopoietic stem cells transplantation for the treatment of elderly patients with acute leukemia.
METHODS: A 71-year-old female patient with acute mononuclear cell leukemia M5b underwent the non-myeloablative allogeneic hematopoietic stem cells transplantation. The donor was the younger brother of the patient who was 60 years old, ABO blood type was the same and the HLA loci were mismatched. The conditioning regimen contained fludarabine, thiotepa, cyclophosphamide and Myleran, human anti-thymocyte globulin(ATG), basiliximab, cyclosporine, mycophenolate mofetil and gamma globulin were used for graft-versus-host disease (GVHD) prophylaxis. The prophylaxis and support therapy of complication after transplantation consisted of Ganciclovir for cytomegalovirus infection, prostaglandin E1, salvia Miltiorrhiza; Heparin and ursodeoxycholic acid for veno-occlusive disease; Granulocyte colony-stimulating factor (G-CSF) 5 μg/kg per day was used when the absolute neutrophil count decreased to 0.5×109 /L. Red cells and platelet were infused if necessary. Peripheral blood stem cells (PBSC) of the donor were mobilized with G-CSF for 7 successive days. PBSC were collected and infused to the patient at the 6th and 7th days.
RESULTS AND CONCLUSION: Hemopoiesis and immunology reconstruction was completed at the 28th day after transplantation. Results of short tandem repeat (STR) detection shows that the DNA from the donor was the same as the patient at the 50th day after transplantation. The patient suffered from hemorrhagic cystitis and sepsis (Burkholderiacepacia) after transplantation for 20-30 days. Two months later, the patient presented with jaundice and hepatic impairment and she was diagnosed as having acute GVHD (liver, grade 3). These were controlled with antibiotics and adjusting the regime of immunosuppressive drugs. These findings indicate that non-myeloablative allogeneic hematopoietic stem cells transplantation based on a pretreatment regime containing fludarabine is safe and effective for elderly acute leukemia patients with a variety of complications.

中图分类号: